Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (ABP) (“Abpro” or the “Company”) ...
Business combination closed November 13, 2024 Raised $10 million of gross proceeds in connection with the business combination Agreements are in place with Yorkville for up to a $50 million standby ...
TipRanks on MSN
FDA clears Abpro’s lead HER2 cancer drug for phase 1
The latest update is out from Abpro Holdings ( (ABP) ).
Abpro successfully closed a business combination with Atlantic Coastal Acquisition Corp II, marking a significant milestone in its journey to provide advanced antibody therapies. The company raised ...
Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Abpro Holdings Inc (Nasdaq: ABP), a biotechnology company with the mission of ...
BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today ...
Get the latest news on Abpro Hldgs stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Abpro Hldgs performance ...
Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback